

Giampaolo Perna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6303249/publications.pdf>

Version: 2024-02-01

199
papers

6,194
citations

61984

43
h-index

110387

64
g-index

203
all docs

203
docs citations

203
times ranked

6690
citing authors

#	ARTICLE	IF	CITATIONS
1	The HPA axis in bipolar disorder: Systematic review and meta-analysis. <i>Psychoneuroendocrinology</i> , 2016, 63, 327-342.	2.7	273
2	Carbon dioxide/oxygen challenge test in panic disorder. <i>Psychiatry Research</i> , 1994, 52, 159-171.	3.3	145
3	Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2888.	4.1	137
4	Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 237-256.	2.4	130
5	Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2017, 8, 148.	2.6	118
6	Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates. <i>Frontiers in Psychiatry</i> , 2016, 7, 138.	2.6	115
7	Approximate Entropy of Respiratory Patterns in Panic Disorder. <i>American Journal of Psychiatry</i> , 2004, 161, 79-87.	7.2	112
8	An update of safety of clinically used atypical antipsychotics. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1329-1347.	2.4	112
9	Neurosteroid secretion in panic disorder. <i>Psychiatry Research</i> , 2003, 118, 107-116.	3.3	107
10	The 35% CO ₂ challenge in panic disorder: Optimization by receiver operating characteristic (ROC) analysis. <i>Journal of Psychiatric Research</i> , 1995, 29, 111-119.	3.1	96
11	Antipanic Efficacy of Paroxetine and Polymorphism within the Promoter of the Serotonin Transporter Gene. <i>Neuropsychopharmacology</i> , 2005, 30, 2230-2235.	5.4	93
12	The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2016, 195, 105-118.	4.1	92
13	CO ₂ -Induced Panic Attacks: A Twin Study. <i>American Journal of Psychiatry</i> , 1998, 155, 1184-1188.	7.2	86
14	35% CO ₂ challenge in panic and mood disorders. <i>Journal of Affective Disorders</i> , 1995, 33, 189-194.	4.1	84
15	Asthma and panic attacks. <i>Biological Psychiatry</i> , 1997, 42, 625-630.	1.3	83
16	Insomnia as a predictor of high-lethality suicide attempts. <i>International Journal of Clinical Practice</i> , 2013, 67, 1311-1316.	1.7	83
17	The revolution of personalized psychiatry: will technology make it happen sooner?. <i>Psychological Medicine</i> , 2018, 48, 705-713.	4.5	77
18	The 35% CO ₂ challenge test in patients with social phobia. <i>Psychiatry Research</i> , 1997, 71, 41-48.	3.3	76

#	ARTICLE	IF	CITATIONS
19	Panic disorder: the role of the balance system. <i>Journal of Psychiatric Research</i> , 2001, 35, 279-286.	3.1	76
20	Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 719.	2.2	74
21	Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. <i>Current Neuropharmacology</i> , 2018, 16, 583-606.	2.9	72
22	Family history of panic disorder and hypersensitivity to CO ₂ in patients with panic disorder. <i>American Journal of Psychiatry</i> , 1996, 153, 1060-1064.	7.2	71
23	Heart rate variability: Can it serve as a marker of mental health resilience?. <i>Journal of Affective Disorders</i> , 2020, 263, 754-761.	4.1	71
24	Psychoimmunoendocrine Aspects of Panic Disorder. <i>Neuropsychobiology</i> , 1992, 26, 12-22.	1.9	68
25	A Novel Ensemble-Based Machine Learning Algorithm to Predict the Conversion From Mild Cognitive Impairment to Alzheimer's Disease Using Socio-Demographic Characteristics, Clinical Information, and Neuropsychological Measures. <i>Frontiers in Neurology</i> , 2019, 10, 756.	2.4	68
26	The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12458-12483.	4.1	66
27	Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression. <i>International Journal of Molecular Sciences</i> , 2015, 16, 1111-1130.	4.1	66
28	Panic Disorder Respiratory Subtype: Psychopathology, Laboratory Challenge Tests, and Response to Treatment. <i>Harvard Review of Psychiatry</i> , 2010, 18, 220-229.	2.1	65
29	Are Anxiety Disorders Associated with Accelerated Aging? A Focus on Neuroprogression. <i>Neural Plasticity</i> , 2016, 2016, 1-19.	2.2	64
30	Hypersensitivity to inhalation of carbon dioxide and panic attacks. <i>Psychiatry Research</i> , 1995, 57, 267-273.	3.3	63
31	A Comparison of Citalopram and Paroxetine in the Treatment of Panic Disorder: A Randomized, Single-Blind Study. <i>Pharmacopsychiatry</i> , 2001, 34, 85-90.	3.3	62
32	Plasma Interleukin-1 β and Tumor Necrosis Factor Concentrations in Obsessive-Compulsive Disorders. <i>Biological Psychiatry</i> , 1997, 42, 976-981.	1.3	61
33	Baseline respiratory parameters in panic disorder: A meta-analysis. <i>Journal of Affective Disorders</i> , 2013, 146, 158-173.	4.1	56
34	Panic disorder: from respiration to the homeostatic brain. <i>Acta Neuropsychiatrica</i> , 2004, 16, 57-67.	2.1	55
35	Plasma interleukin-1 beta concentrations in panic disorder. <i>Psychiatry Research</i> , 1994, 54, 135-142.	3.3	54
36	Panic attacks: a twin study. <i>Psychiatry Research</i> , 1997, 66, 69-71.	3.3	54

#	ARTICLE	IF	CITATIONS
37	The Relationships between Cholesterol and Suicide: An Update. , 2012, 2012, 1-6.		54
38	A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.. CNS and Neurological Disorders - Drug Targets, 2016, 15, 35-44.	1.4	53
39	Pharmacologic Effect of Imipramine, Paroxetine, and Sertraline on 35% Carbon Dioxide Hypersensitivity in Panic Patients. Journal of Clinical Psychopharmacology, 1997, 17, 97-101.	1.4	53
40	A Clinically-Translatable Machine Learning Algorithm for the Prediction of Alzheimer's Disease Conversion in Individuals with Mild and Premild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 61, 1555-1573.	2.6	52
41	Alexithymia, suicidal ideation, and serum lipid levels among drug-naïve outpatients with obsessive-compulsive disorder. Revista Brasileira De Psiquiatria, 2014, 36, 125-130.	1.7	50
42	Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Current Psychiatry Reports, 2016, 18, 23.	4.5	50
43	The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. Frontiers in Psychiatry, 2019, 10, 294.	2.6	50
44	Menstrual cycle-related sensitivity to 35% CO2 in panic patients. Biological Psychiatry, 1995, 37, 528-532.	1.3	46
45	Alexithymia, Suicide Ideation, C-Reactive Protein, and Serum Lipid Levels Among Outpatients with Generalized Anxiety Disorder. Archives of Suicide Research, 2017, 21, 100-112.	2.3	46
46	Dopamine function in obsessive-compulsive disorder: Growth hormone response to apomorphine stimulation. Biological Psychiatry, 1997, 42, 889-897.	1.3	45
47	Reduced cortical thickness and increased gyrfication in generalized anxiety disorder: a 3 T MRI study. Psychological Medicine, 2018, 48, 2001-2010.	4.5	45
48	Modification of 35% Carbon Dioxide Hypersensitivity Across One Week of Treatment With Clomipramine and Fluvoxamine. Journal of Clinical Psychopharmacology, 1997, 17, 173-178.	1.4	45
49	Antipanic Drug Modulation Of 35% CO2 Hyperreactivity and Short-Term Treatment Outcome. Journal of Clinical Psychopharmacology, 2002, 22, 300-308.	1.4	44
50	Comparison of the Treatment with Paroxetine and Reboxetine in Panic Disorder: A Randomized, Single-Blind Study. Pharmacopsychiatry, 2004, 37, 206-210.	3.3	43
51	Atypical Antipsychotics in the Treatment of Acute Bipolar Depression with Mixed Features: A Systematic Review and Exploratory Meta-Analysis of Placebo-Controlled Clinical Trials. International Journal of Molecular Sciences, 2016, 17, 241.	4.1	43
52	Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice. CNS Spectrums, 2017, 22, 342-347.	1.2	43
53	Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. International Clinical Psychopharmacology, 2009, 24, 1-18.	1.7	42
54	Clonazepam in the treatment of psychiatric disorders: an update. International Clinical Psychopharmacology, 2006, 21, 131-142.	1.7	41

#	ARTICLE	IF	CITATIONS
55	Freezing reaction in panic disorder patients associated with anticipatory anxiety. <i>Depression and Anxiety</i> , 2009, 26, 917-921.	4.1	41
56	Sensitivity to 35% Carbon Dioxide in Patients With Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 1999, 60, 379-384.	2.2	41
57	PLASMA CONCENTRATIONS OF INTERLEUKIN-1 β , INTERLEUKIN-6 AND TUMOR NECROSIS FACTOR- α IN ANOREXIA AND BULIMIA NERVOSA. <i>Psychoneuroendocrinology</i> , 1998, 23, 439-447.	2.7	37
58	DSM-III-R personality disorders in panic and obsessive-compulsive disorder: A comparison study. <i>Comprehensive Psychiatry</i> , 1991, 32, 450-457.	3.1	36
59	β -2-Adrenergic receptor sensitivity in panic disorder: I. <i>Psychoneuroendocrinology</i> , 1995, 20, 1-9.	2.7	36
60	Alexithymia, responsibility attitudes and suicide ideation among outpatients with obsessive-compulsive disorder: An exploratory study. <i>Comprehensive Psychiatry</i> , 2015, 58, 82-87.	3.1	36
61	Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday "real world" clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 83-87.	2.4	36
62	Language of dyspnea in panic disorder. <i>Depression and Anxiety</i> , 2004, 20, 32-38.	4.1	35
63	Common and different neural markers in major depression and anxiety disorders: A pilot structural magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2019, 290, 42-50.	1.8	35
64	The somatic marker affecting decisional processes in obsessive-compulsive disorder. <i>Cognitive Neuropsychiatry</i> , 2012, 17, 177-190.	1.3	34
65	Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. <i>Current Pharmaceutical Design</i> , 2019, 25, 381-387.	1.9	33
66	Modulation of Hyperreactivity to 35% CO ₂ After One Week of Treatment With Paroxetine and Reboxetine. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 277-282.	1.4	32
67	The 35% CO ₂ Hyperreactivity and Clinical Symptomatology in Patients With Panic Disorder After 1 Week of Treatment With Citalopram: An Open Study. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 262-267.	1.4	31
68	Are Respiratory Abnormalities Specific for Panic Disorder? A Meta-Analysis. <i>Neuropsychobiology</i> , 2014, 70, 52-60.	1.9	31
69	The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. <i>International Review of Psychiatry</i> , 2017, 29, 425-435.	2.8	31
70	Smoking and respiratory irregularity in panic disorder. <i>Biological Psychiatry</i> , 2004, 56, 393-398.	1.3	30
71	Novel investigational therapeutics for panic disorder. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 491-505.	4.1	30
72	The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 349.	4.1	30

#	ARTICLE	IF	CITATIONS
73	Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first episode major depression: An exploratory study in the "cereal world" everyday clinical practice. <i>Microbial Biotechnology</i> , 2020, 14, 336-342.	1.7	30
74	A segregation study of panic disorder in families of panic patients responsive to the 35% CO2 challenge. <i>Biological Psychiatry</i> , 1999, 46, 815-820.	1.3	29
75	Dizziness, migrainous vertigo and psychiatric disorders. <i>Journal of Laryngology and Otology</i> , 2010, 124, 285-290.	0.8	29
76	Is there a hypersensitive visual alarm system in panic disorder?. <i>Psychiatry Research</i> , 2011, 187, 387-391.	3.3	29
77	A clinically-translatable machine learning algorithm for the prediction of Alzheimer's disease conversion: further evidence of its accuracy via a transfer learning approach. <i>International Psychogeriatrics</i> , 2019, 31, 937-945.	1.0	28
78	A long-term prospective evaluation of first-degree relatives of panic patients who underwent the 35% CO2 challenge. <i>Biological Psychiatry</i> , 1999, 45, 365-367.	1.3	27
79	Inflammatory markers and suicidal attempts in depressed patients: A review. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 583-594.	2.1	27
80	Mental health professionals' attitudes towards mental illness: professional and cultural factors in the INTER NOS study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 325-339.	3.2	27
81	Respiration in Children at Risk for Panic Disorder. <i>Archives of General Psychiatry</i> , 2002, 59, 185.	12.3	26
82	Serotonergic modulation of the balance system in panic disorder: An open study. <i>Depression and Anxiety</i> , 2003, 17, 101-106.	4.1	26
83	Plasma levels of tumor necrosis factor-alpha in patients with panic disorder: effect of alprazolam therapy. <i>Psychiatry Research</i> , 1999, 89, 21-27.	3.3	25
84	Latent classes of emotional and behavioural problems in epidemiological and referred samples and their relations to DSM-IV diagnoses. <i>European Child and Adolescent Psychiatry</i> , 2017, 26, 549-557.	4.7	25
85	The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. <i>Current Pharmaceutical Design</i> , 2016, 22, 5144-5162.	1.9	25
86	An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 554-584.	2.1	25
87	Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review. <i>Current Clinical Pharmacology</i> , 2013, 8, 256-264.	0.6	25
88	Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 65-92.	1.4	25
89	Pharmacologic Effect of Toloxatone on Reactivity to the 35% Carbon Dioxide Challenge. <i>Journal of Clinical Psychopharmacology</i> , 1994, 14, 414-418.	1.4	24
90	Anxiety sensitivity and 35% CO2 reactivity in patients with panic disorder. <i>Journal of Psychosomatic Research</i> , 2003, 54, 573-577.	2.6	24

#	ARTICLE	IF	CITATIONS
91	Treatment of Antipsychotic-Induced Hyperprolactinemia: An Update on the Role of the Dopaminergic Receptors D2 Partial Agonist Aripiprazole. <i>Recent Patents on Endocrine, Metabolic & Immune Drug Discovery</i> , 2014, 8, 30-37.	0.6	24
92	Is there cardiac risk in panic disorder? An updated systematic review. <i>Journal of Affective Disorders</i> , 2016, 194, 38-49.	4.1	24
93	T-lymphocyte cholecystokinin-8 and beta-endorphin concentrations in eating disorders: I. Anorexia nervosa. <i>Psychiatry Research</i> , 1995, 59, 43-50.	3.3	23
94	Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. <i>BioMed Research International</i> , 2017, 2017, 1-17.	1.9	23
95	Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables. <i>Psychiatry Investigation</i> , 2020, 17, 193-206.	1.6	23
96	Dopamine function in obsessive compulsive disorder: cortisol response to acute apomorphine stimulation. <i>Psychoneuroendocrinology</i> , 2000, 25, 301-310.	2.7	22
97	Management of Treatment-Resistant Panic Disorder. <i>Current Treatment Options in Psychiatry</i> , 2017, 4, 371-386.	1.9	22
98	±2-Adrenergic receptor sensitivity in panic disorder: II. <i>Psychoneuroendocrinology</i> , 1995, 20, 11-19.	2.7	21
99	Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1167-1181.	1.8	21
100	Emerging drugs for panic disorder. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 631-645.	2.4	21
101	Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 1827-1836.	2.2	21
102	Effects of Cigarette Smoking on Neuropsychological Performance in Mood Disorders. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e130-e136.	2.2	21
103	Comparison of 35% carbon dioxide reactivity between panic disorder and eating disorder. <i>Psychiatry Research</i> , 2004, 125, 277-283.	3.3	20
104	Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines. <i>Neuropsychobiology</i> , 2011, 63, 1-7.	1.9	20
105	S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study. <i>Scientific World Journal</i> , The, 2013, 2013, 1-5.	2.1	20
106	Prevalence and clinical features associated to bipolar disorder—migraine comorbidity: a systematic review. <i>Comprehensive Psychiatry</i> , 2015, 56, 1-16.	3.1	20
107	Impact of respiratory protective devices on respiration: Implications for panic vulnerability during the COVID-19 pandemic.. <i>Journal of Affective Disorders</i> , 2020, 277, 772-778.	4.1	20
108	Panic and the Brainstem: Clues from Neuroimaging Studies. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 1049-1056.	1.4	20

#	ARTICLE	IF	CITATIONS
109	Religious Coping, Hopelessness, and Suicide Ideation in Subjects with First-Episode Major Depression: An Exploratory Study in the Real World Clinical Practice. <i>Brain Sciences</i> , 2020, 10, 912.	2.3	19
110	Alpha-2-Adrenoceptor Sensitivity in Heroin Addicts with and without Previous Attention Deficit Disorder/Hyperactivity and Conduct Disorder. <i>Neuropsychobiology</i> , 1994, 30, 15-19.	1.9	18
111	Subclinical impairment of lung airways in patients with panic disorder. <i>Biological Psychiatry</i> , 1994, 36, 601-605.	1.3	18
112	T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa. <i>Psychiatry Research</i> , 1995, 59, 51-56.	3.3	18
113	Noradrenergic receptor sensitivity in obsessive-compulsive disorders: I. growth hormone response to clonidine stimulation. <i>Psychiatry Research</i> , 1997, 69, 155-162.	3.3	18
114	Lack of relationship between CO2 reactivity and serotonin transporter gene regulatory region polymorphism in panic disorder. <i>American Journal of Medical Genetics Part A</i> , 2004, 129B, 41-43.	2.4	18
115	Tradução e adaptação transcultural do Questionário de Atividade Física Habitual. <i>Revista De Psiquiatria Clinica</i> , 2010, 37, 16-22.	0.6	18
116	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 483-495.	2.8	18
117	Laboratory, Clinical and Therapeutic Features of Respiratory Panic Disorder Subtype. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 627-635.	1.4	18
118	Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines. <i>International Journal of Molecular Sciences</i> , 2016, 17, 551.	4.1	17
119	Selective serotonin re-uptake inhibitors beyond psychiatry: Are they useful in the treatment of severe, chronic, obstructive pulmonary disease?. <i>Depression and Anxiety</i> , 2004, 20, 203-204.	4.1	16
120	Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. <i>Psychiatry Investigation</i> , 2019, 16, 50-58.	1.6	16
121	Anxiety Sensitivity in Children of Panic Disorder Patients. <i>Child Psychiatry and Human Development</i> , 2005, 35, 315-324.	1.9	15
122	Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration. <i>Psychiatry Research</i> , 1997, 69, 163-168.	3.3	14
123	Childhood Trauma, Temperament, and Character in Subjects With Major Depressive Disorder and Bipolar Disorder. <i>Journal of Nervous and Mental Disease</i> , 2014, 202, 695-698.	1.0	14
124	Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). <i>Journal of Affective Disorders</i> , 2015, 178, 112-120.	4.1	14
125	Personality biomarkers of pathological gambling: A machine learning study. <i>Journal of Neuroscience Methods</i> , 2018, 294, 7-14.	2.5	14
126	Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 317-321.	1.7	14

#	ARTICLE	IF	CITATIONS
127	Vulnerability to 35% CO ₂ of panic disorder patients with a history of respiratory disorders. <i>Psychiatry Research</i> , 2003, 120, 125-130.	3.3	13
128	Self-reported quality of life and clinician-rated functioning in mood and anxiety disorders: Relationships and neuropsychological correlates. <i>Comprehensive Psychiatry</i> , 2014, 55, 979-988.	3.1	13
129	Is panic disorder a disorder of physical fitness? A heuristic proposal. <i>F1000Research</i> , 2018, 7, 294.	1.6	13
130	Are there advances in pharmacotherapy for panic disorder? A systematic review of the past five years. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1357-1368.	1.8	13
131	Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment with Lithium and Clozapine. <i>Current Pharmaceutical Design</i> , 2021, 27, 3293-3304.	1.9	13
132	DSM-III-R personality disorders in panic disorder. <i>Journal of Anxiety Disorders</i> , 1993, 7, 153-161.	3.2	12
133	Anxiety sensitivity and modulation of the serotonergic system in patients with PD. <i>Journal of Anxiety Disorders</i> , 2004, 18, 423-431.	3.2	12
134	Does the "Silver Bullet" Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients. <i>Clinical Practice and Epidemiology in Mental Health</i> , 2016, 12, 142-157.	1.2	12
135	Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician's perspective. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 221-228.	5.0	12
136	Cardiorespiratory response to physical exercise and psychological variables in panic disorder. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 385-389.	1.7	11
137	Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 621.	2.2	11
138	The role of melatonin in mood disorders. <i>ChronoPhysiology and Therapy</i> , 0, , 65.	0.5	11
139	Prevalence of respiratory diseases in patients with panic and obsessive compulsive disorders. <i>Anxiety</i> , 1994, 1, 100-101.	0.4	11
140	<p>Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1957-1970.	2.2	10
141	Carbon dioxide-induced panic attacks and quantitative electroencephalogram in panic disorder patients. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 357-363.	2.6	9
142	Personalized Clinical Approaches to Anxiety Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1191, 489-521.	1.6	9
143	Effect of the serotonin transporter gene and of environment on the continuity of anxiety and depression traits throughout adolescence. <i>Epidemiology and Psychiatric Sciences</i> , 2014, 23, 399-409.	3.9	8
144	Personalized Medicine in Psychiatry: Back to the Future. <i>Personalized Medicine in Psychiatry</i> , 2017, 1-2, 1.	0.1	8

#	ARTICLE	IF	CITATIONS
145	Features of mood associated with high body weight in females with fibromyalgia. <i>Comprehensive Psychiatry</i> , 2018, 80, 57-64.	3.1	8
146	Relapse prevention in panic disorder with pharmacotherapy: where are we now?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1699-1711.	1.8	8
147	The Effect of One-Week Treatment with Venlafaxine on 35% CO2 Hyperreactivity in Patients with Panic Disorder: An Open Study. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 106-108.	1.4	8
148	Understanding anxiety disorders: the psychology and the psychopathology of defence mechanisms against threats. <i>Rivista Di Psichiatria</i> , 2013, 48, 73-5.	0.6	8
149	CO2 challenge in nonclinical subjects. <i>American Journal of Psychiatry</i> , 1997, 154, 886-887.	7.2	7
150	Acoustic startle response in panic disorder. <i>Psychiatry Research</i> , 2010, 176, 254-256.	3.3	7
151	Is there a role for pharmacogenetics in the treatment of panic disorder?. <i>Pharmacogenomics</i> , 2015, 16, 771-774.	1.3	7
152	Role of worry in patients with chronic tinnitus and sensorineural hearing loss: a preliminary study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 4145-4151.	1.6	7
153	Does neuropsychological performance impact on real-life functional achievements in obsessive-compulsive disorder? A preliminary study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 224-231.	2.4	7
154	Effect of family structure and TPH2 G-703T on the stability of dysregulation profile throughout adolescence. <i>Journal of Affective Disorders</i> , 2016, 190, 576-584.	4.1	7
155	Childhood maltreatment history for guiding personalized antidepressant choice in major depressive disorder: Preliminary results from a systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110208.	4.8	7
156	COVID-19 and panic disorder: clinical considerations for the most physical of mental disorders. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 110-111.	1.7	6
157	Experimental Drugs for Panic Disorder: An Updated Systematic Review. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 441-459.	3.2	6
158	Oxidative Stress in the Early Stage of Psychosis. <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 1457-1470.	2.1	6
159	Elevated C-reactive protein levels across diagnoses: The first comparison among inpatients with major depressive disorder, bipolar disorder, or obsessive-compulsive disorder. <i>Journal of Psychosomatic Research</i> , 2021, 150, 110604.	2.6	6
160	First-onset major depression during the COVID-19 pandemic: A predictive machine learning model. <i>Journal of Affective Disorders</i> , 2022, 310, 75-86.	4.1	6
161	Temperament, Character and Anxiety Sensitivity in Panic Disorder: A High-Risk Study. <i>Psychopathology</i> , 2012, 45, 300-304.	1.5	5
162	Personalized medicine in panic disorder: where are we now? A meta-regression analysis. <i>Personalized Medicine in Psychiatry</i> , 2017, 1-2, 26-38.	0.1	5

#	ARTICLE	IF	CITATIONS
163	Growth hormone response to growth hormone-releasing hormone stimulation in obsessive-compulsive disorder. <i>Psychiatry Research</i> , 1998, 81, 293-299.	3.3	4
164	Psychiatric Disorders and Childhood Parental Loss in Obesity: Relationship with the Mode of Weight Gain. <i>Journal of Loss and Trauma</i> , 2016, 21, 213-224.	1.5	4
165	Controlled-release pregabalin in the treatment of fibromyalgia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 617-623.	2.8	4
166	Childhood adversities in patients with fibromyalgia: are they related to comorbid lifetime major depression?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 112-118.	0.8	4
167	Predicting New-Onset Psychiatric Disorders Throughout the COVID-19 Pandemic: A Machine Learning Approach. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022, 34, 233-246.	1.8	4
168	Pregnancy and Respiratory Nocturnal Panic Attacks. <i>Canadian Journal of Psychiatry</i> , 2003, 48, 573-574.	1.9	3
169	Urinary incontinence and diarrhoea associated with the switch from oral to injectable risperidone. <i>Acta Neuropsychiatrica</i> , 2013, 25, 119-121.	2.1	3
170	Does gender influence cognitive function in non-psychotic depression?. <i>Personalized Medicine in Psychiatry</i> , 2017, 4-6, 25-31.	0.1	3
171	Short-Term Psychiatric Rehabilitation in Major Depressive and Bipolar Disorders: Neuropsychological-Psychosocial Outcomes. <i>Psychiatry Investigation</i> , 2017, 14, 8.	1.6	3
172	When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia. , 2019, , 349-367.		3
173	The Co-Morbidity between Bipolar and Panic Disorder in Fibromyalgia Syndrome. <i>Journal of Clinical Medicine</i> , 2020, 9, 3619.	2.4	3
174	“Precision” or “personalized” psychiatry: different terms “ same content?. <i>Fortschritte Der Neurologie Psychiatrie</i> , 2020, 88, 759-766.	0.5	3
175	Psychopharmacological treatment in borderline personality disorder: A pilot observational study in a real-world setting. <i>Psychiatry Research</i> , 2021, 295, 113556.	3.3	3
176	Anxiety, depression, and suicide: epidemiology, pathophysiology, and prevention. , 0, , 93-100.		2
177	Mediation effect of recent loss events on weight gain in obese people who experienced childhood parental death or separation. <i>Journal of Health Psychology</i> , 2017, 22, 101-110.	2.3	2
178	Atypical Antipsychotics in Major Depressive Disorder. , 2018, , 257-268.		2
179	Commentary: Cognitive Behavioral Therapy vs. Eye Movement Desensitization and Reprocessing for Treating Panic Disorder: A Randomized Controlled Trial. <i>Frontiers in Psychology</i> , 2018, 9, 1061.	2.1	2
180	The role of spatial store and executive strategy in spatial working memory: a comparison between patients with obsessive-compulsive disorder and controls. <i>Cognitive Neuropsychiatry</i> , 2019, 24, 14-27.	1.3	2

#	ARTICLE	IF	CITATIONS
181	Prediction of illness remission in patients with Obsessive-Compulsive Disorder with supervised machine learning. <i>Journal of Affective Disorders</i> , 2022, 296, 117-125.	4.1	2
182	No Sex Differences in Self-Reported Childhood Maltreatment in Major Depressive and Bipolar Disorders: A Retrospective Study. <i>Brain Sciences</i> , 2022, 12, 804.	2.3	2
183	Respiration and Anxiety. , 0, , 251-267.		1
184	Comments on "Heart rate and respiratory response to doxapram in patients with panic disorder". <i>Psychiatry Research</i> , 2016, 239, 362-363.	3.3	1
185	Cariprazine (RGH-188): a new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression?. <i>Minerva Psychiatry</i> , 2017, 58, .	0.3	1
186	Expert opinion in panic disorder: The impact of COVID-19-related fears, protective devices, and lockdown on panic and agoraphobia. <i>Personalized Medicine in Psychiatry</i> , 2021, 27-28, 100080.	0.1	1
187	The "Emotional Side" of Subjective Tinnitus. , 0, , .		1
188	Alexithymia and Breast Cancer Surgery: A Systematic Review. <i>British Journal of Medicine and Medical Research</i> , 2016, 15, 1-11.	0.2	1
189	Is panic disorder associated with clinical severity of fibromyalgia? A preliminary study in a tertiary-care centre. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S99-105.	0.8	1
190	Citalopram and panic disorder. , 1996, 4, 253-253.		0
191	Different Effects of Cigarette Smoking on Neuropsychological Performance in Psychiatric Disorders. , 2016, , 305-316.		0
192	Precision Psychiatry: Personalized Clinical Approach to Depression. , 2018, , 245-261.		0
193	751 Heart Rate and Heart Rate Variability During Sleep As Biomarkers for Depression. <i>Sleep</i> , 2021, 44, A293-A293.	1.1	0
194	253 Better and faster automatic sleep staging with artificial intelligence. <i>Sleep</i> , 2021, 44, A102-A102.	1.1	0
195	Special issue editorial: Personalized medicine in psychiatry in the COVID-19 era: Fighting the impact of the pandemic on mental health. <i>Personalized Medicine in Psychiatry</i> , 2021, 27-28, 100077.	0.1	0
196	Can personalized medicine mitigate confirmation bias in mental health?. <i>Revista Brasileira De Psiquiatria</i> , 2021, , .	1.7	0
197	S-Adenosyl-L-Methionine for Major Depressive Disorder. , 2016, , 847-854.		0
198	Panic Disorder, Is It Really a Mental Disorder? From Body Functions to the Homeostatic Brain. , 2016, , 93-112.		0

#	ARTICLE	IF	CITATIONS
199	Neuroprogression in anxiety disorders. , 2019, , 129-146.		0